Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer

Li,Hui; Xie,Ling; Lai,Ren-Seng

doi:10.3892/mco.2012.34

Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer

Authors:
- Hui Li
- Ling Xie
- Ren-Seng Lai
View Affiliations

Affiliations: Department of Pathology, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (TCM), Nanjing, P.R. China
Published online on: October 15, 2012 https://doi.org/10.3892/mco.2012.34
Pages: 195-199

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical studies suggest that the mRNA expression level of excision repair cross complementing group 1 gene (ERCC1) is associated with epidermal growth factor receptor (EGFR) mutation and breast cancer susceptibility 1 gene (BRCA1) mRNA expression in non‑small cell lung cancer (NSCLC). In this study, the correlation between EGFR mutation status and ERCC1 and BRCA1 gene expression in Chinese NSCLC patients was examined. Real-time polymerase chain reaction (PCR) and direct sequencing were used to detect mRNA expression levels and EGFR mutation status, respectively in microdissected formalin-fixed paraffin-embedded non-small cell lung cancer tissues. EGFR mutations were detected in 27/103 patients (26.2%) and were found to be gender‑related (P=0.001). The BRCA1 mRNA expression level was associated with histology, while there was no association with ERCC1. For the EGFR mutant‑type, a high BRCA1 gene expression was detected in 2 cases (20.0%) and a low expression in 8 cases (80.0%), while for EGFR wild‑type, a high BRCA1 gene expression was detected in 20 cases (43.5%) and a low expression in 26 cases (56.5%). There was no difference in the one‑year survival period, according to results obtained for either the ERCC1 or BRCA1 mRNA expression levels. EGFR mutations in NSCLC samples are more likely to express low ERCC1 and BRCA1 mRNA levels. In these latter samples, a statistically significant difference was observed. However, to examine their correlation and clinical outcomes, additional studies are required.

View Figures

View References

1.	Simon GR, Sharma S, Cantor A, et al: ERCC 1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 127:978–983. 2005.
2.	Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small cell lung cancer. J Clin Oncol. 25:2747–2754. 2007.
3.	Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG and Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63:6221–6228. 2003.
4.	Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ and Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004.
5.	Hotta K, Kiura K, Toyooka S, et al: Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2:632–637. 2007.
6.	Gandara DR, Grimminger P, Mack PC, et al: Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 5:1933–1938. 2010.
7.	Tian SW, Li H, Xie L, et al: The associated analysis of ERCC1 gene polymorphism in regulatory region and mRNA Q-PCR expression. Chin Clin Oncol. 12:1073–1076. 2009.
8.	Reed E: ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res. 11:6100–6102. 2005.
9.	Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325. 2004.
10.	Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 8:2286–2291. 2002.
11.	Shan L, Han ZG, Liu L, et al: ERCC1 and BRCA1 expressions in advanced non-small cell lung cancer and their relationship with cisplatin resistance. Tumor. 29:571–574. 2009.(In Chinese).
12.	Rosell R, Cecere F, Santarpia M, et al: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 6:323–331. 2006.
13.	Mullan PB, Quinn JE and Harkin DP: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 25:5854–5863. 2006.
14.	Kennedy RD, Quinn JE, Mullan PB, et al: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 96:1659–1668. 2004.
15.	Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res. 284:31–53. 2003.
16.	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.
17.	Wang JR, Zhang SP, Lai RS, et al: Intron 1 (CA) n dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and responsiveness of molecular targeted therapy in lung cancer. Mod Pathol. 17:2113–2117. 2009.
18.	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.
19.	Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 23:8081–8092. 2005.
20.	Wu JU, Yub CJ, Shih JY, et al: Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer. 67:348–354. 2010.
21.	Wu JY, Shih JY, Yang CH, et al: Second-line treatments after first-line gefitinib therapy in advanced non-small cell lung cancer. Int J Cancer. 126:247–255. 2010.
22.	Li L, Wang H, Yang ES, et al: Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 68:9141–9146. 2008.
23.	Bandyopadhyay D, Mandal M, Adam L, et al: Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 273:1568–1573. 1998.
24.	Rosell R, Perez-Roca L, Sanchez JJ, et al: Customized treatment in non-small cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One. 4:e51332009.
25.	Rosell R, Tarón M and O’Brate A: Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol. 13:101–109. 2001.
26.	Taron M, Rosell R, Felip E, et al: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 13:2443–2449. 2004.